Detail akcie Halozyme Thrp online

Business Summary: Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Halozyme Therapeutics, Inc. revenues increased 26% to $829.3M. Net income increased 39% to $281.6M. Revenues reflect Royalties segment increase of 24% to $447.9M, Hylenex segment increase of 80% to $130.8M, United States segment increase of 34% to $587.2M, Belgium segment increase from $2.1M to $58.4M. Net income benefited from Investment and other income increase from $1M to $16.3M (income).